RecruitingPhase 2NCT06295588

Clinical Trial of the Seaweed Supplement Fucoidan in Survivors of Cancer

Minimizing Fatigue and Inflammation in Survivors of Cancer: A Pilot Randomized Clinical Trial of the Seaweed Supplement Fucoidan

Sponsor

University of Rochester

Enrollment

40 participants

Start Date

Jul 26, 2025

Study Type

INTERVENTIONAL

Conditions

Fatigue Inflammation

Summary

To determine the feasibility of an 8-week fucoidan supplement intervention for patients with fatigue post-cancer treatment and assess changes in fatigue, frailty, and inflammation.

Eligibility

Min Age: 18 Years

Inclusion Criteria7

Survivors of cancer
Age 18 or older
Speak and understand English
Have completed surgery, radiation, and/or systemic intravenous anticancer therapy (e.g., chemotherapy, targeted therapy, immunotherapy) ≤10 years prior to enrollment.
Have a baseline level of fatigue, as determined by reporting a score of 4 or higher for the question, "In the last week, how bad was your worst fatigue on a scale from 0-10?"
Be willing to commit to the fucoidan supplement dosing and delivery method, to complete evaluation instruments, and to attend all study visits.
Completed Informed Consent

Exclusion Criteria6

Current warfarin or other anti-coagulation medication use.
Current use of supplements that contain fucoidan
Any allergy to fucoidan
Be diagnosed with a major psychiatric illness requiring hospitalization within the last year.
Be diagnosed with dementia.
Be pregnant or nursing